Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.31 |
| ▸ | PER2 | O15055 | 2/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059149 | 0.84 | BRD4 (0.36) | HMGCRALDH1A1NR1I2PDE4DRORC | |
| SCHEMBL1062157 | 0.82 | MAPK14 (0.46) | PDE4DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1067521 | 0.81 | RORC (0.36) | RORCPTGS2MAPK14MAPK13MAPK12 | |
| SCHEMBL1063029 | 0.79 | HSP90AB1 (0.46) | HMGCRALDH1A1NR1I2PDE4DRORC | |
| SCHEMBL6911074 | 0.78 | BRD4 (0.39) | HMGCRRORCMAPK14MAPK13MAPK12 | |
| SCHEMBL12122428 | 0.74 | CDK4 (0.34) | RORCPTGS2MAPK14MAPK13MAPK12 | |
| SCHEMBL1065461 | 0.74 | CDK4 (0.34) | RORCPTGS2MAPK14MAPK13MAPK12 | |
| SCHEMBL1065266 | 0.74 | MAPK14 (0.39) | HMGCRRORCMAPK14MAPK11 | |
| SCHEMBL1059261 | 0.74 | CDK5 (0.39) | ALDH1A1RORC | |
| SCHEMBL1064545 | 0.69 | HSP90AB1 (0.43) | RORCMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110009625-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | MAPKAPK2, MAPK8, CREBBP | HMGCR 4395/4885ALDH1A1 4185/4885CYP3A4 4740/4885 |
| US-20110009625-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | HMGCR 4387/4885ALDH1A1 4362/4885CYP3A4 4783/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | HMGCR 4471/4885ALDH1A1 4298/4885CYP3A4 4613/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | HMGCR 4387/4885ALDH1A1 4362/4885CYP3A4 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.